About this trial
The primary goal of this study is to assess the impact of an app that reminds patients irradiated for high-risk prostate cancer to drink water prior to each radiotherapy session on the number of bladder volumes \<200 ml during the radiotherapy course and to demonstrate that this number is lower than without using an app (historical control group).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Histologically proven high-risk prostate cancer
Indication for definitive normo-fractionated radiotherapy
Possession of a smart phone and the ability to use it
Bladder volume at CT-simulation <200 ml
Disqualifiers
Radiotherapy of pelvic lymph nodes
Expected non-compliance
Trial design
Single group
Treatments tested in this trial
Reminder App
DeviceThe purpose of the app is to remind patients irradiated for prostate cancer in an intuitive, unobtrusive and supportive way to drink 300 ml of water 45 minutes prior to each radiation session.
Treatment groups
Trial outcomes
Primary outcomes
Number of fractions with bladder volumes <200 ml at 35 fractions
The primary endpoint is the number of radiation fractions with bladder volumes \<200 ml after 35 fractions of radiotherapy. The bladder volume at each radiation fraction are calculated from the corresponding Cone-Beam Computed Tomography (CBCT).
Secondary outcomes
Number of radiation fractions with bladder volumes <200 ml at the end of radiotherapy
This secondary endpoint is the number of radiation fractions with bladder volumes \<200 ml at the of the radiotherapy course. The bladder volume at each radiation fraction are calculated from the corresponding Cone-Beam Computed Tomography (CBCT).
Rate of patient satisfaction with the reminder app
Patient satisfaction with the reminder app will be assessed with a specific questionnaire.
Degree of the impact of the reminder app
Impact of the reminder app on the use of health technology will be assessed with a specific questionnaire.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University Hospital Schleswig-Holstein
Lead sponsor
University of Southern Denmark
Collaborator
Medical School Hamburg
Collaborator
This trial is not recruiting at the moment. You can still explore other options: